Business
Fennec Pharmaceuticals Announces FDA Acceptance for Filing of New Drug Application Resubmission for PEDMARK™
~ Prescription Drug User Fee Act (PDUFA) target action date set for September 23, 2022 ~ RESEARCH TRIANGLE PARK, N.C., , April 27, 2022 (GLOBE NEWSWIRE) --
About this update from Fennec Pharmaceuticals Inc.
[{"type":"text","content":"~ Prescription Drug User Fee Act (PDUFA) target action date set for September 23, 2022 ~\nRESEARCH TRIANGLE PARK, N.C., , April 27, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s resubmitted New Drug Application (NDA) for PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients one month to","length":742,"tagName":"div"}]